10x Genomics is trading at $87.76, down 10.21%, with biotech-sector weakness as relevant context; no fresh company-specific announcement explaining the October 6 decline was found.
- The biotech ETF XBI was down 2.50% during the session, relevant context that does not explain the full drop.
- The latest company news identified was September 29 product announcements.
- The broader market was reported higher; recent gains preceded today’s reversal, and available evidence identifies no new company-specific catalyst.